Emergent Biosolutions (EBS)

Emergent’s commercial products include naloxone nasal sprays such as NARCAN and KLOXXADO, which are used to reverse the effects of opioid overdose. These products place the company at the centre of a major public health issue, where access, distribution and awareness are important drivers of demand. Alongside its commercial business, Emergent supplies medical countermeasure products including BioThrax, ACAM2000, ANTHRASIL, BAT, raxibacumab and other specialised therapies or vaccines used in preparedness programmes.

The company also operates a services business through its bioservices platform, providing development and manufacturing capabilities for biologics, vaccines and related products. This segment can support both internal programmes and third-party customers, although contract manufacturing is exposed to capacity utilisation, quality standards, regulatory oversight and programme timing.

Emergent is distinctive because much of its business sits at the intersection of biotechnology, national security and public health policy. Revenue can be influenced by government procurement cycles, stockpiling decisions, regulatory approvals, product supply reliability and the urgency of specific health threats. For investors, the company offers exposure to specialised medical products that are often difficult to develop and manufacture, but it also carries risks tied to customer concentration, compliance requirements and changing public health priorities.